香连化滞水丸剂的制备及质量检测OA
Preparation and quality evaluation of Xianglian Huazhi water-pills formulation
本研究对香连化滞水丸剂开展工艺优化与质量评价,在传统处方(黄连、木香等12味药)基础上,以玉米淀粉为辅料并采用塑制法制丸,控制丸径约5 mm,经60℃热风干燥得均一圆整的水丸;通过性状与外观一致性、丸重与含水量等指标测定来评价成品稳定性,并采用显微鉴别与薄层色谱鉴别完成同一性鉴别(特征显微颗粒、Rf与显色均与对照品相符);采用C18-HPLC外标法(λ=350 nm,乙腈与0.1%磷酸体积比为42∶58,含0.10%十二烷基磺酸钠),系统适用性达标,于tR≈19.24 min检出与对照品一致的小檗碱峰,测得样品中盐酸小檗碱含量为4.0 mg/g,符合《中华人民共和国药典》(2020年版)规定(≥2 mg/g).结果表明,本研究建立工艺可稳定制得适用于伴侣动物口服的香连化滞水丸,处方同一性明确,关键成分含量可控,成品质量均一且具备良好可制备性,具有推广应用前景.
This study aimed to optimize the manufacturing process and established quality evaluation for the Xianglian Huazhi water-pills formulation.Based on the traditional prescription(12 crude drugs including Coptidis Rhizoma and Aucklandiae Radix),pills were prepared by the molding method with corn starch as excipient,controlled at 5 mm in diameter,and dried with hot air at 60℃to obtain uniform and round pellets.Product stability was assessed via appearance/consistency,pill weight,and moisture content.Identity was confirmed by microscopy and TLC,with characteristic microscopic features and Rf/color reactions consistent with references.Quantification employed C18-HPLC with the external-standard method(λ=350 nm,acetonitrile-0.1%phosphoric acid=42∶58,V/V,containing 0.10%sodium dodecyl sulfate);system suitability met the preset criteria,and a berberine peak consistent with the reference was detected at tR≈ 19.24 min,giving a content of 4.0 mg/g,which complies with the Chinese Pharmacopoeia(2020)specification(≥2 mg/g).These results indicate that the established process reliably produces Xianglian Huazhi water pills suitable for companion animals,with clear prescription identity,controllable marker content,and uniform quality,supporting good manufacturability and prospects for broader application.
胡重重;刘嘉怡;万天;范开
中国农业大学动物医学院,北京 100193中国农业大学动物医学院,北京 100193中国农业大学动物医学院,北京 100193中国农业大学动物医学院,北京 100193
农业科技
香连化滞丸水丸剂型药学研究质量控制适口性
Xianglian Huazhi pillswater-pillsdosage formpharmaceutical studyquality controlpalatability
《中兽医医药杂志》 2026 (1)
57-61,封3,6
"十四五"国家重点研发计划(2022YFD1801102)
评论